Agenus | AGEN - Selling And Administration Expenses


Agenus reported $6.21M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Agenus USD 6.21M 4.34M Mar/2026
Amgen USD 1.72B 134M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Celldex Therapeutics USD 13.1M 1.65M Jun/2026
CSL USD 1.23B 498M Dec/2025
Eli Lilly USD 3.43B 496M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Glaxosmithkline GBP 2.12B 1.44B Mar/2026
Incyte USD 351.73M 23.64M Jun/2026
Intrexon USD 10.31M 41K Jun/2024
J&J USD 6.42B 381M Jun/2026
Jiangsu Hengrui CNY 2.81B 191.05M Mar/2026
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck EUR 1.57B 49M Jun/2026
Merck USD 2.89B 219M Jun/2026
Northwest Biotherapeutics USD 6.54M 534K Mar/2026
Novartis USD 3.24B 101M Jun/2026
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Rigel Pharmaceuticals USD 27.04M 1M Sep/2024
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Veracyte USD 55.71M 4.87M Jun/2026